3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
32
Multiple Myeloma
26
Neoplasms
25
Recurrence
23
Melanoma
19
Leukemia, Myeloid, Acute
16
Breast Neoplasms
15
Prostatic Neoplasms
12
Pancreatic Neoplasms
11
Glioblastoma
11
Sarcoma
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lung Neoplasms
9
Ovarian Neoplasms
8
Lymphoma
8
Glioma
8
Colorectal Neoplasms
8
Small Cell Lung Carcinoma
7
Lymphoma, Large B-Cell, Diffuse
7
Carcinoma, Renal Cell
7
Lymphoma, Non-Hodgkin
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Gastrointestinal Stromal Tumors
6
Cholangiocarcinoma
6
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
5
Neoplasm Metastasis
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Thyroid Neoplasms
4
Lymphoma, Mantle-Cell
4
Interventions
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Expanded_access
×
EGFR T790M Mutation Positive NSCLC
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available